We’re Joining Forces! BioLife Solutions announces intent to purchase SAVSU Technologies shares outstanding. On July 8, 2019, BioLife issued a press release announcing that the company will purchase the remaining 56% of shares of SAVSU that BioLife does not presently own. The acquisition is expected to close within 45 days.
BioLife’s relationship with SAVSU spans six years, during the development and growth of the evo® Cold Chain 2.0TM system, encompassing evo® hardware and evo.is® software. Since January 2019, SAVSU has supported more than 50 clinical trial-stage, commercial-stage cell and gene therapy companies that have adopted evo technology.
The evo®Cold Chain 2.0TMsystem: The evo hardware is smart and features advanced communications and sensor technology imbedded into connected shipping containers designed and matched to deliver cells alive and functioning, at the indicated temperature. Technologically advanced; the evo hardware is engineered to exceed the challenges of temperature ranges that include controlled room temperature (CRT; PCM), 2 – 8ºC (wet ice/PCM), -80ºC (dry ice), and -196ºC (liquid nitrogen dry vapor). The evo.is software cloud-based platform provides real-time communication and sensor visibility with the evo hardware and much more. Through evo.is, the user manages a fleet of evo containers, maintains a database of addresses, schedules shipments and returns. User configurable, the software sends notifications, alerts and prompts the recipient to unpack the payload within a pre-specified period of time.
The acquisition of SAVSU is expected to strengthen BioLife’s position as a leading supplier of disruptive, enabling solutions and technologically advanced devices to cell and gene therapy manufacturers.
BioLife’s CryoStor and HypoThermosol are best in class biopreservation solutions embedded in more than 300 customer clinical applications. CryoStor and HypoThermosol are used to preserve cell viability and function at multiple points within the cell therapy manufacturing workflow. The manufacturing workflow often includes a shipping component that requires transportation of starting material or finished product. evo hardware and evo.is software are then used to preserve cell viability and function during shipment. But what if your gene therapy does not contain cells but must be shipped frozen? evo is your answer, too. In addition, since cryopreserved cellular therapies must also be thawed, BioLife previously acquired Astero Bio and the ThawSTAR® line of thawing devices for automated thawing.
BioLife continues to grow to serve you, so let’s have a conversation detailing how our advanced capabilities may address one or more of your needs. Contact us online at Ask the Scientists. Call us at 1.866.6543 (toll-free in North America) or direct (1.425.402.1400) for more information or to place an order. Our website, www.biolifesolutions.com, is also a wealth of information. Our Evidence Library contains more than 425 articles, abstracts and posters citing the biopreservation efficacy of CryoStor and HypoThermosol plus additional links to US FDA Master Files, Patents, BioPreservation Media Products in Customer Clinical Trials, CryoStor cryopreservation protocol and cryopreservation video.
